YES! and Northeast Baptist Hospital Partner to Host Innovative Cancer Treatment Seminar

Wednesday 22 May 2013
Free Event for Patients, Caregivers and Medical Community Proves There is HOPE for Patients with Liver Cancer

SAN ANTONIO (MAY 22, 2013) – YES! Beat Liver Tumors, a nonprofit organization dedicated to the support of patients diagnosed with primary or metastatic liver tumors, will host a patient and caregiver event in conjunction with Northeast Baptist Hospital at noon on Thursday, May 30. YES! advocates are working with liver cancer specialists from Northeast Baptist Hospital to raise awareness for liver tumor treatment options in the greater San Antonio area.

“Every year more than 200,000 Americans are diagnosed with liver tumors, and many are told, as I was, to get their affairs in order,” said Suzanne Lindley, co-founder and executive director of YES! and 13-year cancer survivor. “We want to let patients and physicians know there are treatment options available – liver tumors are no longer a death sentence.”

The Liver Seminar series, taking place at medical centers across the country, is designed to provide patients and caregivers the opportunity to hear Lindley’s empowering story that there is hope despite the devastating diagnosis. Joining Lindley are surgical oncologists Dr. Morton S. Kahlenberg and Dr. Dennis L. Rousseau, medical oncologist Dr. Vijay Gunuganti and interventional oncologist Dr. Rajiv Vasan, all from Baptist Health System. The doctors will discuss emerging therapies they are offering in their multidisciplinary approach to care, such as Selective Internal Radiation Therapy (SIRT) using yttrium-90 microspheres that directly target liver tumors while sparing healthy liver tissue.

“This event will give patients in our area a great opportunity to hear Suzanne’s inspirational survival story and learn more about liver directed treatment options,” said Dr. Vasan. “At Northeast Baptist Hospital we are utilizing some of the latest therapies available to treat liver tumors, and we are pleased to have the opportunity to share this information with patients and the community.”

For more information on the free Liver Seminar, or to register for the event, please visit or call 877-937-7478. Please note that space is limited. Reservations will be taken on a first-come, first-serve basis. Complimentary food and drinks will be provided.

About YES!

YES! is a grassroots organization that was created out of the need to provide cancer patients with experience and insight that can increase the treatment possibilities available for those who have liver involvement. It is made up of survivors who have undergone targeted therapy for liver metastases (cancer that has spread to the liver) or hepatocellular (liver) cancer. We are an organization dedicated to sharing timely and reliable information. We hope this sharing enables informed choices regarding treatment and recovery. We ultimately strive to enhance the quality of life for all of those affected by liver related tumors. For more information visit or call the Survivor Line at 877-937-7478.

About Baptist Health System

Baptist Health System is a trusted provider of health care in San Antonio and South Texas.  The System includes five acute-care hospitals (Baptist Medical Center, Mission Trail Baptist Hospital, North Central Baptist Hospital, Northeast Baptist Hospital, and St. Luke’s Baptist Hospital) which offer 1,674 licensed beds.  All five hospitals have earned Accredited Chest Pain Center designation, as well as Primary Stroke Center Certification.  Medicare has designated each as Texas’ only Medicare Value Based Care Centers.

The system also includes Baptist Regional Children’s Center, Baptist Breast Center, Baptist Cancer Center, HealthLink wellness and fitness center and physical rehabilitation centers.  Other entities include Baptist M&S Imaging Centers, community health and wellness programs, ambulatory services, medical office buildings and School of Health Professions.  Baptist Health System supports the work of Faith Family Clinics, Baptist Emergency Hospitals, San Antonio AirLIFE air medical transport and other health-related services and affiliations.  The system is part of Vanguard Health Systems, based out of Nashville, Tennessee.

# # #


Media Contacts:

Lexi Rudolph



Ashley Cardenas


Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



Now leaving

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for journalists only

By clicking "Yes" you are confirming that you are a journalist. If you are not a journalist, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.